AB
ZVRA icon

Amalgamated Bank’s Zevra Therapeutics ZVRA Stock Holding History

Amalgamated Bank’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,750
Closed -$16K – 2835
2025
Q4 		$16K Sell
1,750
-75
-4% -$709 ﹤0.01% 2226
2025
Q3 		$17K Hold
1,825
– – ﹤0.01% 2218
2025
Q2 		$16K Hold
1,825
– – ﹤0.01% 2217
2025
Q1 		$14K Buy
1,825
+655
+56% +$5.21K ﹤0.01% 2235
2024
Q4 		$10K Hold
1,170
– – ﹤0.01% 2456
2024
Q3 		$8K Hold
1,170
– – ﹤0.01% 2588
2024
Q2 		$6K Hold
1,170
– – ﹤0.01% 2733
2024
Q1 		$7K Sell
1,170
-1,856
-61% -$11.4K ﹤0.01% 2616
2023
Q4 		$20K Sell
3,026
-348
-10% -$1.63K ﹤0.01% 2658
2023
Q3 		$16K Hold
3,374
– – ﹤0.01% 2765
2023
Q2 		$17K Buy
+3,374
New +$18.2K ﹤0.01% 2823
2022
Q2 		– Sell
-4,181
Closed -$21K – 3224
2022
Q1 		$21K Buy
+4,181
New +$26.6K ﹤0.01% 2800

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Amalgamated Bank's ZVRA Position: Q1 2026 in Review

Amalgamated Bank sold out of Zevra Therapeutics (ZVRA) in Q1 2026, closing a stake of 1,750 shares — an estimated $16K sold.

Amalgamated Bank first reported a position in ZVRA in Q1 2022 and held it in 12 quarters. The position peaked at $21K in Q1 2022. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

  • Amalgamated Bank reported no remaining Zevra Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 1,750 Zevra Therapeutics shares in Q1 2026, an estimated $16K.
  • Amalgamated Bank first reported a position in Zevra Therapeutics in Q1 2022 and held it in 12 quarters.
  • Amalgamated Bank's Zevra Therapeutics position peaked at $21K in Q1 2022.
  • 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.